Restarting Tirzepatide After Interruption: Guideline Summary

Pre-Restart Laboratory Assessment

The American College of Cardiology recommends obtaining a lipid panel to assess baseline cardiovascular risk and establish a reference point for monitoring cardiometabolic improvements with tirzepatide 1
A comprehensive metabolic panel, including liver enzymes and renal function, provides baseline organ function assessment, though tirzepatide requires no dose adjustment across all stages of chronic kidney disease 1, 2
Hemoglobin A1C and fasting glucose should be checked to screen for progression to prediabetes or type 2 diabetes during the 6-month treatment gap, particularly important given class 3 obesity 1, 2
Blood pressure measurement is essential, as weight changes and tirzepatide treatment can affect blood pressure and may necessitate antihypertensive medication adjustments 2
Thyroid function testing may be considered if not recently checked, though this is not a tirzepatide-specific requirement 3

Tirzepatide does not carry the same monitoring requirements as medications like statins, which necessitate baseline and follow-up liver enzyme and creatine kinase monitoring 4, 5, 6
The medication's safety profile is well-established, with gastrointestinal effects being the most common adverse events rather than laboratory abnormalities 4, 5, 6

Pancreatitis risk requires clinical vigilance for persistent severe abdominal pain rather than routine laboratory surveillance 1, 2
Gallbladder disease is monitored clinically through symptom assessment, not laboratory testing 1, 2
No hepatotoxicity monitoring is required, unlike statins which mandate ALT/AST surveillance at specific intervals 4, 5, 6

Restart at the initial 2.5 mg dose and follow the standard titration schedule, as the patient has been off medication for 6 months, which exceeds the 3-dose threshold that would warrant restarting titration 1
The standard titration schedule is:
Week Dose
1-4 2.5 mg weekly
5-8 5 mg weekly
9-12 7.5 mg weekly (if needed)
13-16 10 mg weekly (if needed)
17+ 15 mg weekly (maximum dose) [1]

Assess at 4 weeks after restart for gastrointestinal tolerance, weight loss progress, and blood pressure 1
Evaluate treatment response at 12-16 weeks on the maximum tolerated therapeutic dose to determine if continuation is appropriate, with patients achieving ≥5% weight loss likely to benefit from continued use 1, 2
Monitor at least every 3 months after reaching maintenance dose for weight stability, blood pressure, cardiovascular risk factors, and medication adherence 1, 2

Absolute contraindications that must be ruled out before restarting include personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 1, 2

Do not assume the patient can restart at their previous dose after a 6-month gap—the standard titration schedule must be followed to minimize gastrointestinal adverse effects 1
Do not order unnecessary "monitoring labs" like routine liver enzymes or amylase/lipase without clinical indication, as these are not part of tirzepatide management protocols 1, 2
Do not skip the baseline metabolic assessment, as the 6-month gap represents an opportunity to reassess cardiovascular risk factors and screen for diabetes progression 1